A detailed history of Axq Capital, LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 20,435 shares of ALT stock, worth $85,213. This represents 0.03% of its overall portfolio holdings.

Number of Shares
20,435
Previous 41,282 50.5%
Holding current value
$85,213
Previous $160 Million 51.78%
% of portfolio
0.03%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

SELL
$3.38 - $4.76 $70,462 - $99,231
-20,847 Reduced 50.5%
20,435 $77 Million
Q2 2025

Aug 12, 2025

BUY
$3.5 - $7.71 $144,487 - $318,284
41,282 New
41,282 $160 Million
Q4 2024

Feb 11, 2025

SELL
$6.02 - $9.85 $66,864 - $109,403
-11,107 Reduced 47.27%
12,388 $89.3 Million
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $129,222 - $190,309
23,495 New
23,495 $144 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $204M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Axq Capital, LP Portfolio

Follow Axq Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.